Pre-Open Stock Movers

Lexicon Pharmaceuticals (NASDAQ: LXRX) 38% HIGHER; Citi upgraded from Neutral to Buy with a price target of $6.00 (from $2.10).

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that Dan Jedda has joined the company, reporting to Katrina Lake. Jedda will be appointed CFO effective December 9, 2020. Dan Jedda joins the company from Amazon where he was Vice President and CFO for Digital Video (including Amazon Studios), Digital Music, and the Advertising and Corporate Development organizations.

Smartsheet (NYSE: SMAR) 16.7% HIGHER; reported Q3 EPS of ($0.12), $0.09 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $98.9 million versus the consensus estimate of $94.59 million. Smartsheet sees Q4 2021 EPS of ($0.15)-($0.13), versus the consensus of ($0.13). Smartsheet sees Q4 2021 revenue of $102-103 million, versus the consensus of $99.5 million.

QuantumScape (NYSE: QS) 16% HIGHER; released performance data demonstrating that its technology addresses fundamental issues holding back widespread adoption of high-energy density solid-state batteries, including charge time (current density), cycle life, safety, and operating temperature.

Hollysys Automation (NASDAQ: HOLI) 15.1% HIGHER; $15.47/share offer from Consortium disclosed.

Luminar Technologies (NASDAQ: LAZR) 12.% HIGHER; Northland Capital Markets downgraded from Outperform to Market Perform with a price target of $41.00.

Penumbra, Inc. (NYSE: PEN) 11.2% LOWER; Quintessential Capital Management issues a new report on its short target

Conn's (NASDAQ: CONN) 10% LOWER; reported Q3 EPS of $0.25, $0.01 better than the analyst estimate of $0.24. Revenue for the quarter came in at $334.16 million versus the consensus estimate of $345.19 million.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) 7.7% LOWER; announced an underwritten public offering of its common stock.

iBio, Inc. (NYSEA: IBIO) 6.4% LOWER; announced an underwritten public offering of its common stock. In addition, iBio has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) 6% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) 5% LOWER; announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock.

Sutro Biopharma, Inc. (Nasdaq: STRO) 4.5% LOWER; announced a proposed underwritten public offering in which it intends to offer and sell 5,000,000 shares of its common stock

GrowGeneration Corp. (NASDAQ: GRWG) 4.3% LOWER; announced that it has publicly filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission relating to a proposed follow-on public offering raising $125,000,000.

ON Semiconductor Corporation (NASDAQ: ON) 4% HIGHER; announced that Hassane El-Khoury has been selected as the company’s new president, chief executive officer and member of its board of directors, starting from December 07.

Sequans Communications S.A. (NYSE: SQNS) 2.8% LOWER; announced the launch of an underwritten public secondary offering of its American Depositary Shares (the “ADSs”). Each ADS represents four ordinary shares of the Company, nominal value €0.02 per share. The ADSs to be sold in the proposed offering will be offered by Nokomis Capital Master Fund, LP (“Nokomis”) and will be issued pursuant to the conversion of $12.4 million in principal and accrued paid-in-kind interest of Sequans’ convertible notes.

MicroStrategy® Incorporated (Nasdaq: MSTR) 2.7% LOWER; announced that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2025 (the notes) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the Securities Act). MicroStrategy also expects to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $60 million aggregate principal amount of the notes. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed.

HealthEquity (NASDAQ: HQY) 2.5% LOWER; reported Q3 EPS of $0.43, $0.07 better than the analyst estimate of $0.36. Revenue for the quarter came in at $179.4 million versus the consensus estimate of $176.78 million. HealthEquity sees FY2021 EPS of $1.55-$1.61, versus the consensus of $1.56. HealthEquity sees FY2021 revenue of $725-731 million, versus the consensus of $728.06 million.

Coupa Software (NASDAQ: COUP) 2% HIGHER; reported Q3 EPS of $0.18, $0.15 better than the analyst estimate of $0.03. Revenue for the quarter came in at $133 million versus the consensus estimate of $123.8 million. Coupa Software sees Q4 2021 EPS of ($0.11)-($0.13), versus the consensus of $0.01. Coupa Software sees Q4 2021 revenue of $145-146 million, versus the consensus of $129.9 million.